Aetna Policy Update Expands TMS Availability for Adolescents With Depression

The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications. Aetna is one of the largest health plans in the country with over 19.4 million lives covered through its commercial policies nationwide. The TMS policy update is effective immediately. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com. About Neuronetics MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medic ...